



Developing first in class drugs targeting cardiovascular diseases

Midcap Event (extract) - October 2014

This document has been prepared by Quantum Genomics (“the Company”) solely for use at this presentation. By receiving this presentation and taking part to this meeting you acknowledge that you have read the following restrictions.

This document is confidential and is not to be reproduced by any person, nor to be distributed. Certain information contained in this presentation includes forward-looking statements. Forward-looking statements are not guarantees of future performance of Quantum Genomics and its actual financial condition, actual results of operations and cash flows and the development of the industry in which it operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, even if Quantum Genomics’s financial condition, results of operations and cash flows and the development of the industry in which Quantum Genomics operates are consistent with the forward-looking statements contained in this presentation, those results or developments may not be indicative of results or developments in future periods. Quantum Genomics does not undertake, nor does it have any obligation, to provide updates or to revise any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation. Quantum Genomics takes no responsibility for the use of this information by any person.

The information contained in this presentation has not been subject to independent verification. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained herein. The information set out herein is subject to updating, completion, revision, verification and amendment and such information may change materially. Quantum Genomics is under no obligation to keep current the information contained in this presentation and any opinion expressed in them is subject to change without notice. Quantum Genomics shall have no liability whatsoever (in negligence or otherwise) for any loss arising from any use of this document or its contents or otherwise arising in connection with this document. It is not the purpose of this presentation to provide, and you may not rely on this presentation as providing, a complete or comprehensive analysis of Quantum Genomics’s financial or commercial position or prospects. A detailed description of the business and financial conditions of Quantum Genomics and a section “Facteurs de risques” (“risk factors”) are included in the Offering Circular. Copies of the Offering Circular are available on the web site of the AMF (www.amf-france.org) and of Quantum Genomics (www.quantum-genomics.com).

This document does not constitute an offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any shares of Quantum Genomics in the United States or any other jurisdiction and nor any part of it shall form the basis of, or be relied upon in connection with, any contract, commitment or investment decision in relation thereto.

This presentation is directed only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended, the “Financial Promotion Order”), (ii) are persons falling within Articles 49(2)(a) to (d) (“High Net Worth Companies, Unincorporated Associations, etc”) of the Financial Promotion Order, (iii) are persons to whom an invitation or inducement to engage in investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000) in connection with the issue or sale of any shares may otherwise lawfully be communicated or caused to be communicated (all such persons together being referred to as “Relevant Persons”).

This presentation is directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this document relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. This presentation is solely for your information on a confidential basis and may not be reproduced, redistributed or published (whether internally or externally to your company), directly or indirectly, in whole or in part, to any other person. Neither this document nor any copy of it may be taken, transmitted into or distributed in the United States of America, Canada, Australia, Japan or to any resident of these countries. The distribution of this document in other jurisdictions may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Any failure to comply with these restrictions may constitute a violation of applicable securities law.

1/3

Of adults and more, depending on countries has high blood pressure. With the proportion going up to one in two for people aged 50 and above⁽¹⁾

9.4 Million

Deaths worldwide every year due to complications of high blood pressure⁽¹⁾

1/3

Are dying due to cardiovascular diseases. 1st cause of death with 17 million deaths in the world each year⁽¹⁾



“Hyper-pressure contributes to nearly 9.4 million deaths due to heart disease and stroke every year and, together, these two diseases are the number one cause of death worldwide. And, hyper-pressure also increases the risk of kidney failure, blindness and several other conditions. It often occurs together with other risk factors like obesity, diabetes and high cholesterol - increasing the health risk even further.”

WHO Chief Dr Margaret Chan – World Health Day April 07, 2013

\$ 40 billion

Global anti-hypertensive drugs market in 2013⁽²⁾

\$ 108 billion

Global heart failure costs for the world economy every year⁽³⁾


- Sources :
- (1) WHO (World Health Organization) - A global brief on hypertension, Silent killer, global public health crisis (2013),
 - (2) the pharmaletter (June 2014),
 - (3) the annual global economic burden of heart failure. Int J Cardiol (2014)

Hypertension : the « silent killer » leading to global public health crisis

% Uncontrolled hypertension

Hypertension prevalence in Europe

> 140/90 mmHg



➤ **> 50% of treated patients still have high blood pressure**


Using : Diuretics, beta-blockers, ACEi, ARBs, Calcium Channel blockers

➤ **x2 the risk of death from stroke or heart attack**

Increase of 20/10 mmHg is associated to this risk

➤ **A strong need to develop new classes of drugs to improve hypertension control**

BAPAI : a new therapeutic approach to cure hypertension and associated cardiovascular diseases




➤ Quantum Genomics, the « *BAPAI company* », is developing first in class treatment targeting a new pharmacological pathway in the brain

➤ Benefiting from more than 20 years of the highest standard academic research in Europe



COLLÈGE
DE FRANCE
—1530—






➤ BAPAI is an innovative drug that targets a new central pharmacological pathway leading to both antihypertensive effects and cardioprotection

The first targeted population : LRHV Low Renin High Vasopressin patients


- **Mostly uncontrolled or poorly controlled : LRHV patients**
 - LRHV is overexpressed in elderly, Asian, Afro-American and Hispanic populations
 - In LRHV population, 30% of deaths are due to uncontrolled hypertension
 - ACEs and ARBs drugs are not a therapeutic option for those patients





➤ A unique biopharmaceutical company developing new centrally acting drugs targeting Aminopeptidase A

A well-balanced pipeline of new drugs



HYPERTENSION

QGC 001

First-in-class

Stand alone treatment of Hypertension



QGC 011

Combination

Combination with existing antihypertensive drugs



QGC 006

Best-in-class

Optimized stand alone treatment using BAPAI



CONGESTIVE HEART FAILURE

QGC 101

First-in-class









Preventing & Treating Congestive Heart Failure



- **Mechanism of action: a brain penetrating prodrug**

- QGC001 is able to release in the brain the specific and selective APA inhibitor EC33 which blocks the production of brain angiotensin III

- **Success of preclinical studies**


- **Stability profile**   Chemical stability and properties compatible with the development of a solid dosage form
- **Pharmacokinetics**   High bioavailability in dogs
- **Toxicity**   No toxicity observed in rats and dogs up to 1,000 mg/kg, no cardiac toxicity, no genotoxicity, no hepatotoxicity
- **Efficacy**   Efficacy demonstrated in hypertensive rats (SHR & DOCA Salt rats) at 15 mg/kg per os.

 **Approval for initiating the first in human Phase I clinical study**

QGC 001

First-in-class

Stand alone treatment of
Hypertension



Phase Ia ✓

2012

Randomized, double blind,
placebo controlled study of single
ascending doses in healthy
volunteers

Phase Ib ✓

2013

Randomized, double blind,
placebo controlled study of
multiple ascending doses in
healthy volunteers



Phase IIa

Q4 2014

Initiation of a phase IIa in
hypertensive patients


➤ *Positive : overall safety
and tolerability of
QGC001 up to 2g*

➤ *Positive : overall safety
and tolerability of
QGC001 up to 750mg
twice a day and no food
interaction*

QGC 011

Combo BAPAI / IEC

Treatment of hypertension in
combination



- **An alternative product to currently marketed antihypertensive drugs**
 - Therapeutic solution for patients poorly or not controlled by existing treatments
 - Synergistic action that allows to dosage reduction and minimized side effects
- **Preclinical results demonstrating high interest in combination with the Angiotensin Converting Enzyme inhibitor, Enalapril (Renitec/Vasotec)**
- **Potential for development in combination with Angiotensin II receptor antagonists (sartans) e.g Valsartan (Angiotan/Diovan)**

➤ Increasing the market potential of the *BAPAI platform*

QGC 006

Best-in-class

Optimized treatment
of hypertension as monotherapy

Target
discovery

Identification
of active
compounds

Preclinical
studies

Clinical studies
Phase I

Clinical studies
Phase II


- **Extended research program to identify new BAPAI's**
 - Improved inhibition, better selectivity versus other enzymes or other receptors
- **2nd generation drug**
 - 10 times more potent inhibitor of Aminopeptidase A compared to QGC001

➤ **Reinforcement of the patents' portfolio of Quantum Genomics
PLUS increase the lifetime of *BAPAI's* drugs**

QGC 101

First-in-class

Prevention and treatment of
congestive heart failure



- **APA plays a major role in several diseases**

- The potential of BAPAI has been demonstrated in the prevention and treatment of congestive heart failure in a first study in rodents

- **Two preclinical studies for QGC101**

- Proof of efficiency in a rodent model
 - Proof of efficiency in a dog model

➤ **Widening the potential of *BAPAI* towards other diseases**

➤ **Widening towards animal health market**

➤ **Signature in January 2014 of a collaborative agreement, with licence option, with a major company in the domain of animal health to treat heart failure in dogs**

Next steps in the development process



HYPERTENSION

QGC 001

First-in-class

Treatment of hypertension as monotherapy



Proof of efficacy in hypertensive patients

QGC 011

Combination

Treatment of hypertension in combination



*Regulatory Preclinical results
Pharmacokinetics and toxicology (rats and dogs)*

QGC 006

Best-in-class

Optimized treatment of hypertension as monotherapy




Proof of efficacy single dose in hypertensive rats

CONGESTIVE
HEART FAILURE


QGC 101

First-in-class

Prevention and treatment of congestive heart failure



Proof of efficacy repeated doses (post infarction rats and dogs models) and readiness for phase II





QUANTUM GENOMICS SA
Immeuble L'Odysée
2-12, Chemin des Femmes
91300 Massy, France
T : + 33 (0)1.60.13.76.84
marc.karako@quantum-genomics.com